Purified forms of rofecoxib, methods of manufacture and use
Raymond D. Skwierczynski, Andover, MA (US); Bradford C. Sippy, Acton, MA (US); Jean-Marie Schneider, Magnaville (FR); Simon H. Drouin, Saint-Hyacinthe (CA); and Charles Guerin, Mantes la Ville (FR)
Assigned to Tremeau Pharmaceuticals, Inc., Concord, MA (US)
Filed by Tremeau Pharmaceuticals, Inc., Concord, MA (US)
Filed on Jul. 1, 2022, as Appl. No. 17/856,549.
Application 17/856,549 is a continuation of application No. 17/186,697, filed on Feb. 26, 2021, granted, now 11,576,890.
Application 17/186,697 is a continuation of application No. 16/716,242, filed on Dec. 16, 2019, granted, now 10,987,337, issued on Apr. 27, 2021.
Application 16/716,242 is a continuation of application No. PCT/US2019/061178, filed on Nov. 13, 2019.
Claims priority of provisional application 62/770,563, filed on Nov. 21, 2018.
Prior Publication US 2022/0378736 A1, Dec. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/341 (2006.01)
CPC A61K 31/341 (2013.01)
36 Claims
10. A pharmaceutical composition comprising about 12.5 mg rofecoxib or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, wherein the rofecoxib or a pharmaceutically acceptable salt thereof comprises less than 0.05% of 4-[4-(methylsulfonyl)phenyl]-3-phenyl-5-hydroxyfuran-2-one.